References
- 1. Y. Shang, C. Pan, X. Yang, M. Zhong, X. Shang, Z. Wu, Z. Yu, W. Zhang, Q. Zhong and X. Zheng, L. Sang, L. Jiang, J. Zhang, W. Xiong, J. Liu and D. Chen, Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China, Ann. Intensive Care 10(1) (2020) Article ID 73 (24 pages); https://doi.org/10.1186/s13613-020-00689-110.1186/s13613-020-00689-1727565732506258
- 2. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S. Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang and D. D. Ho, Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1.7, Nature 593 (2021) 130–135; https://doi.org/10.1038/s41586-021-03398-210.1038/s41586-021-03398-233684923
- 3. S. Su, G. Wong, W. Shi, J. Liu, A. K. Lai, J. Zhou, W. Liu, Y. Bi and G .F. Gao, Epidemiology, genetic recombination, and pathogenesis of coronaviruses, Trends Microbiol. 24(6) (2016) 490–502; https://doi.org/10.1016/j.tim.2016.03.00310.1016/j.tim.2016.03.003712551127012512
- 4. K. Liu, Y.-Y. Fang, Y. Deng, W. Liu, M.-F. Wang, J.-P. Ma, W. Xiao, Y.-N. Wang, M.-H. Zhong, C.-H. Li, G.-C. Li and H.-G. Liu, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin. Med. J. 133(9) (2020) 1025–1031; https://doi.org/10.1097/CM9.000000000000074410.1097/CM9.0000000000000744714727732044814
- 5. C. W. K. Lam, M. H. M. Chan and C. K. Wong, Severe acute respiratory syndrome: Clinical and laboratory manifestations, Clin. Biochem. Rev. 25(2) (2004) 121–132.
- 6. S. Lu, Q. Zhou, L. Huang, Q. Shi, S. Zhao, Z. Wang, W. Li, Y. Tang, Y. Ma, X. Luo, T. Fukuoka, H. S. Ahn, M. S. Lee, Z. Luo, E. Liu, Y. Chen, C. Zhou and D. Peng (on behalf of COVID-19 Evidence and Recommendations Working Group), Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis, Ann. Transl. Med. 8(10) (2020) Article ID 627 (21 pages); https://doi.org/10.21037/atm-20-330710.21037/atm-20-3307729062832566564
- 7. M. Merad and J. C. Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat. Rev. Immunol. 20 (2020) 355–362; https://doi.org/10.1038/s41577-020-0331-410.1038/s41577-020-0331-4720139532376901
- 8. M. Z. Tay, C. M. Poh, L. Rénia, P. A. MacAry and L. P. Ng, The trinity of COVID-19: immunity, inflamma tion and intervention, Nat. Rev. Immunol. 20 (2020) 363–374; https://doi.org/10.1038/s41577-020-0311-810.1038/s41577-020-0311-8718767232346093
- 9. A. G. Harriso, T. Lin and P. Wang, Mechanisms of SARS-CoV-2 transmission and pathogenesis, Trends Immunol. 41(12) (2020) 1100–1115; http://doi.org/10.1016/j.it.2020.10.00410.1016/j.it.2020.10.004755677933132005
- 10. X. Sun, T. Wang, D. Cai, Z. Hu, J. Chen, H. Liao, L. Zhi, H. Wei, Z. Zhang, Y. Qiu and J. Wang, Cytokine storm intervention in the early stages of COVID-19 pneumonia, Cytokine Growth Factor Rev. 53 (2020) 38–42; https://doi.org/10.1016/j.cytogfr.2020.04.00210.1016/j.cytogfr.2020.04.002718252732360420
- 11. Q. Ruan, K. Yang, W. Wang, L. Jiang and J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med. 46 (2020) 846–848; https://doi.org/10.1007/s00134-020-05991-x10.1007/s00134-020-05991-x708011632125452
- 12. K. Yuki, M. Fujiogi and S. Koutsogiannaki, COVID-19 pathophysiology: A review, Clin. Immunol. 215 (2020) Article ID 108427; https://doi.org/10.1016/j.clim.2020.10842710.1016/j.clim.2020.108427
- 13. X. Fang, Q. Mei, T. Yang, L. Li, Y. Wang, F. Tong, S. Geng and A. Pan, Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19, J. Infect. 81(1) (2020) 147–178; https://doi.10.1016/j.jinf.2020.03.039
- 14. V. Selvaraj, K. Dapaah-Afriyie, A. Finn and T. P. Flanigan, Short-term dexamethasone in Sars-CoV-2 patients, RI Med. J. 103 (2020) 39–43; https://doi.org/10.1101/2020.06.19.2010917310.1101/2020.06.19.20109173
- 15. P. Sinha, A. Mostaghim, C. G. Bielick, A. McLaughlin, D. H. Hamer, L. M. Wetzler, N. Bhadelia, M. A. Fagan, B. P. Linas, S. A. Assoumou, M. H. Ieong, N. H. Lin, E. R, Cooper, K. D. Brade, L. F. White, T. F. Barlam and M. Sagar, Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge, Int. J. Infect. Dis. 99 (2020) 28–33; https://doi.org/10.1016/j.ijid.2020.07.02310.1016/j.ijid.2020.07.023
- 16. D. Wu, Q. Rao and W. Zhang, The natural course of COVID-19 patients without clinical intervention, J. Med. Virol. 93 (2021) 5527–5537; https://doi.org/10.1002/jmv.2708710.1002/jmv.27087
- 17. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395(10223) (2020) 497–506; https://doi.org/10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5
- 18. J. Phua, L. Weng, L. Ling, M. Egi, C. M. Lim, J. V. Divatia, B. R. Shrestha, Y. M. Arabi, J. Ng, C. D. Gomersall, M. Nishimura, Y. Koh and B. Du, Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, Lancet Respir. Med. 8 (2020) 506–517; https://doi.org/10.1016/S2213-2600(20)30161-210.1016/S2213-2600(20)30161-2
- 19. Z. Xiang, J. Liu, D. Shi, W. Chen, J. Li, R. Yan, Y. Bi, W. Hu, Z. Zhu, Y. Yu and Z. Yang, Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels, Int. J. Biol. Sci. 16(13) (2020) 2382–2391; https://doi.org/10.7150/ijbs.4765210.7150/ijbs.47652
- 20. M. Lester, A. Sahin and A. Pasyar, The use of dexamethasone in the treatment of COVID-19, Ann. Med. Surg. (London) 56 (2020) 218–219; https://doi.org/10.1016/j.amsu.2020.07.00410.1016/j.amsu.2020.07.004
- 21. P. Horby, W. S. Lim, J. R. Emberson, M. Mafham, J. L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L. C. Chappell, S. N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J. K. Baillie, R. Haynes, M. J. Landray (The RECOVERY Collaborative Group), Dexamethasone in hospitalized patients with Covid-19 – preliminary report, N. Engl. J. Med. 384(8) (2021) 693–704; https://doi.org/10.1056/NEJMoa202143610.1056/NEJMoa2021436
- 22. C. D. Russell, J. E. Millar and J. K. Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet 395 (2020) 473–475; https://doi.org/10.1016/S0140-6736(20)30317-210.1016/S0140-6736(20)30317-2
- 23. J. Villar, C. Ferrando, D. Martínez, A. Ambrós, T. Muñoz, J. A. Soler, G. Aguilar, F. Alba, E. González-Higueras, L. A. Conesa, C. Martín-Rodríguez, F. J. Díaz-Domínguez, P. Serna-Grande, R. Rivas, J. Ferreres, Javier Belda, L. Capilla, A. Tallet, J. M. Añón, R. L. Fernández and J. M. González-Martín, Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir. Med. 8 (2020) 267–276; https://doi.org/10.1016/S2213-2600(19)30417-510.1016/S2213-2600(19)30417-5
- 24. A. A. Ordonez, M. Maiga, S. Gupta, E. A. Weinstein, W. R. Bishai and S. K. Jain, Novel adjunctive therapies for the treatment of tuberculosis, Curr. Mol. Med. 14(3) (2014) 385–395; https://doi.org/10.2174/156652401366613111811243110.2174/1566524013666131118112431448477424236454
- 25. A. Grzanka, M. Misiołek, W. Golusiński and J. Jarząb, Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis, Eur. Arch. Oto-Rhino-Laryngol. 268 (2011) 247–253; https://doi.org/10.1007/s00405-010-1330-z10.1007/s00405-010-1330-z302118620628753
- 26. I. B. Mitre-Aguilar, A. J. Cabrera-Quintero and A. Zentella-Dehesa, Genomic and non-genomic effects of glucocorticoids: implications for breast cancer, Int. J. Clin. Exp. Pathol. 8(1) (2015) 1–10.
- 27. M. Karn, S. Yonghang and S. Ghimire, Corticosteroids in COVID-19: We should be mindful of their acute toxicities, J. Clin. Pharmacol. 61(10) (2021) 1301–1302; https://doi.org/10.1002/jcph.193610.1002/jcph.1936842674534196415
- 28. S. S. Hasan, T. Capstick, R. Ahmed, C. S. Kow, F. Mazhar, H. A. Merchant and S. R. Zaidi, Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a syste matic review and meta-analysis, Expert Rev. Respir. Med. 14(11) (2020) 1149–1163; https://doi.org/10.1080/17476348.2020.180436510.1080/17476348.2020.1804365754496832734777
- 29. F. Chen, L. Hao, S. Zhu, X. Yang, W. Shi, K. Zheng, T. Wang and H. Chen, Potential adverse effects of dexamethasone therapy on COVID-19 patients: Review and recommendations, Infect. Dis. Ther. 10(4) (2021) 1907–1931; https://doi.org/10.1007/s40121-021-00500-z10.1007/s40121-021-00500-z829804434296386
- 30. R. Zhao, H. Wang, X. Wang and F. Feng, Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis, Osteoporos. Int. 28 (2017) 1027–1034; https://doi.org.10.1007/s00198-016-3824-z
- 31. X. Li and X. Ma, Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit. Care 24 (2020) Article ID 198 (5 pages); https://doi.org/10.1186/s13054-020-02911-910.1186/s13054-020-02911-9720279232375845
- 32. M. Yasir, A. Goyal, P. Bansal and S. Sonthalia, Corticosteroid Adverse Effects, in StatPearls [Internet], StatPearls Publishing, Treasure Island (FL, USA) 2022.
- 33. L. Kornel, A. V. Prancan, N. Kanamarlapudi, J. Hynes and E. Kuzianik, Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo, Endocr. Res. 21(1–2) (1995) 203–210; https://doi.org/10.3109/0743580950903043610.3109/074358095090304367588382
- 34. K. Smets and P. Vanhaesebrouck, Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease, Eur. J. Pediatr. 155 (1996) 573–575.10.1007/BF019579078831080
- 35. L. Berbegal, F. J. DeLeon and J. F. Silvestre, Hypersensitivity reactions to corticosteroids, Actas Dermo-Sifiliogr. (Engl.) 107(2) (2016) 107–115; https://doi.org/10.1016/j.adengl.2016.01.00310.1016/j.adengl.2016.01.003
- 36. J. E. Henriksen, F. Alford, G. M. Ward and H. Beck-Nielsen, Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients, Diabetologia 40 (1997) 1439–1448; https://doi.org/10.1007/s00125005084710.1007/s001250050847
- 37. G. F. Keenan, Management of complications of glucocorticoid therapy, Clin. Chest Med. 18(3) (1997) 507–520; https://doi.org/10.1016/S0272-5231(05)70398-110.1016/S0272-5231(05)70398-1
- 38. H. O. Conn and T. Poynard, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J. Intern. Med. 236(6) (1994) 619–632; https://doi.org/10.1111/j.1365-2796.1994.tb00855.x10.1111/j.1365-2796.1994.tb00855.x7989897
- 39. N. K. Lee, S. Kim, S. B. Hong, S. J. Lee, T. U. Kim, H. Ryu, J. W. Lee, J. Y. Kim and H. B. Suh, CT diagnosis of non-traumatic gastrointestinal perforation: an emphasis on the causes, Jpn. J. Radiol. 38 (2020) 101–111; https://doi.org/10.1007/s11604-019-00910-710.1007/s11604-019-00910-731848888
- 40. P. C. Ng, K. G. Brownlee and P. R. Dear, Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia, Arch. Dis. Child. 66 (1991) 1164–1166; https://doi.org/10.1136/adc.66.10_Spec_No.116410.1136/adc.66.10_Spec_No.116415902771750771
- 41. R. Alexanian, M. A. Dimopoulos, K. Delasalle and B. Barlogie, Primary dexamethasone treatment of multiple myeloma, Blood 80(4) (1992) 887–890; https://doi.org/10.1182/blood.V80.4.887.88710.1182/blood.V80.4.887.887
- 42. M. A. Kerachian, C. Séguin and E. J. Harvey, Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action, J. Steroid Biochem. Mol. Biol. 114(3) (2009) 121–128; https://doi.org/10.1016/j.jsbmb.2009.02.00710.1016/j.jsbmb.2009.02.007712623519429441
- 43. X. Wu, C. Geng, W. Sun and M. Tan, Incidence and risk factors of osteonecrosis of femoral head in multiple myeloma patients undergoing dexamethasone-based regimens, BioMed Res. Int. 2020 (2020) Article ID 7126982 (7 pages); https://doi.org/10.1155/2020/712698210.1155/2020/7126982724641132509867
- 44. N. K. Rahayu and A. Emily, Clinical profile of steroid-induced glaucoma in Bali Mandara Eye Hospital year 2019, Intisari Sains Medis 12(1) (2021) 6–8; https://doi.org/10.15562/ism.v12i1.872
- 45. G. S. Zode, A. B. Sharma, X. Lin, C. C. Searby, K. Bugge, G. H. Kim, A. F. Clark and V. C. Sheffield, Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma, J. Clin. Invest. 124 (2014) 1956–1965; https://doi.org/10.1172/JCI6977410.1172/JCI69774400153224691439
- 46. M. D. Kamitsuka, M. A. Williams, D. A. Nyberg, K. A. Fox, D. L. Lee and D. Hickok, Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia, J. Perinatol. 15 (1995) 359–363.
- 47. D. J. Cranefield, D. E. Odd, J. E. Harding and R. L. Teele, High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone, Pediatr. Radiol. 34 (2004) 138–142; https://doi.org/10.1007/s00247-003-1090-710.1007/s00247-003-1090-714624322
- 48. K. Gendo, S. D. Sullivan, P. Lozano, J. A. Finkelstein, A. Fuhlbrigge and K. B. Weiss, Resource costs for asthma-related care among pediatric patients in managed care, Ann. Allergy Asthma Immunol. 91(3) (2003) 251–257; https://doi.org/10.1016/S1081-1206(10)63526-010.1016/S1081-1206(10)63526-0
- 49. D. C. Perantie and E. S. Brown, Corticosteroids, immune suppression, and psychosis, Curr. Psychiatry Rep. 4 (2002) 171–176; https://doi.org/10.1007/s11920-002-0023-810.1007/s11920-002-0023-812003678
- 50. R. Hajjo, D. A. Sabbah and S. K. Bardaweel, Chemocentric informatics analysis: Dexamethasone versus combination therapy for COVID-19, ACS Omega 5(46) (2020) 29765–29779; https://doi.org/10.1021/acsomega.0c0359710.1021/acsomega.0c03597768966233251412
- 51. T. Izumo, M. Inomata, N. Kuse, N. Awano, M. Tone, K. Takada, Y. Muto, K. Fujimoto, A. Ueda and M. Hayashi, Combination therapy with remdesivir, dexamethasone, and tocilizumab in patients with severe corona virus disease 2019 in clinical practice, Res. Square - preprint posted 16 Oct, 2020; https://doi.org/10.21203/rs.3.rs-91919/v110.21203/rs.3.rs-91919/v1
- 52. P. Baghaei, F. Dastan, M. Marjani, A. Moniri, Z. Abtahian, S. Ghadimi, M. Valizadeh, J. Heshmatnia, M. S. Mirenayat, A. Abedini, A. Kiani, A. Eslaminejad, S. M. Hashemian, H. Jamaati, A. Zali, A. A. Velayati and P. Tabarsi, Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of severe COVID-19 infected inpatients, Int. Immunopharmacol. 92 (2021) Article ID 107329; https://doi.org/10.1016/j.intimp.2020.10732910.1016/j.intimp.2020.107329776280133412395
- 53. T. Izumo, N. Kuse, N. Awano, M. Tone, K. Sakamoto, K. Takada, Y. Muto, K. Fujimoto, A. Saiki, Y. Ito, H. Matsumoto and M. Inomata, Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19, Respir. Invest. 59(6) (2021) 799–803; https://doi.org/10.1016/j.resinv.2021.07.00410.1016/j.resinv.2021.07.004835267734413006
- 54. J. V. Fahy and B. F. Dickey, Airway mucus function and dysfunction, N. Engl. J. Med. 363 (2010) 2233–2247; https://doi.org/10.1056/NEJMra091006110.1056/NEJMra0910061404873621121836
- 55. A. J. Lier, J. J. Tuan, M. W. Davis, N. Paulson, D. McManus, S. Campbell, D. R. Peaper and J. E. Topal, Case report: Disseminated strongyloidiasis in a patient with COVID-19, Am. J. Trop. Med. Hyg. 103(4) (2020) 1590–1592; https://doi.org/10.4269/ajtmh.20-069910.4269/ajtmh.20-0699754380332830642
- 56. G. U. Meduri, L. Bridges, M. C. Shih, P. E. Marik, R. C. Siemieniuk and M. Kocak, Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature, Intens. Care Med. 42 (2016) 829–840; https://doi.org/10.1007/s00134-015-4095-410.1007/s00134-015-4095-426508525
- 57. A. K. Singh, S. Majumdar, R. Singh and A. Misra, Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective, Diabetes Metab. Syndr. Clin. Res. Rev. 14(5) (2020) 971–978; https://doi.org/10.1016/j.dsx.2020.06.05410.1016/j.dsx.2020.06.054732071332610262
- 58. S. A. Amin, K. Ghosh, S. Gayen and T. Jha, Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors, J. Biomol. Struct. Dyn. 39(13) (2021) 4764–4773; https://doi.org/10.1080/07391102.2020.178094610.1080/07391102.2020.1780946
- 59. J. J. Condemi, S. Goldstein, C. Kalberg, S. Yancey, A. Emmett and K. Rickard, The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma, Ann. Allergy, Asthma Immunol. 82(4) (1999) 383–389; https://doi.org/10.1016/S1081-1206(10)63288-710.1016/S1081-1206(10)63288-7
- 60. A. Woolcock, B. O. Lundback, N. Ringdal and L. A. Jacques, Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids, Am. J. Respir. Crit. Care Med. 153(5) (1996) 1481–1488; https://doi.org/10.1164/ajrccm.153.5.863059010.1164/ajrccm.153.5.86305908630590
- 61. J. L. Black, B. G. Oliver and M. Roth, Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists, Chest 136(4) (2009) 1095–1100; https://doi.org/10.1378/chest.09-035410.1378/chest.09-035419809050
- 62. L. Fuso, N. Mores, S. Valente, M. Malerba and P. Montuschi, Long-acting beta-agonists and their association with inhaled corticosteroids in COPD, Curr. Med. Chem. 20(12) (2013) 1477–1495; https://doi.org/10.2174/092986731132012000310.2174/092986731132012000323409722
- 63. L. J. Nannini, P. Poole, S. J. Milan and A. Kesterton, Combined Corticosteroid and Long-Acting Beta2-Agonist in One Inhaler versus Inhaled Corticosteroids Alone for Chronic Obstructive Pulmonary Disease, in: Cochrane Database Systematic Reviews (Issue 8. Art. No.: CD006826), Cochrane Library 2013, Wiley, Hoboken (NJ, USA), 2014; https://doi.org/10.1002/14651858.CD006826.pub210.1002/14651858.CD006826.pub2648627423990350
- 64. P. Sinha and B. P. Linas, Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality, Clin. Infect. Dis. 73(11) (2021) 2116–2118; https://doi.org/10.1093/cid/ciab409
- 65. D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M. White, M. J. O’Meara, V. V. Rezelj, J. Z. Guo, D. L. Swaney, T. A. Tummino, R. Hüttenhain, R. M. Kaake, A. L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B. J. Polacco, H. Braberg, J. M. Fabius, M. Eckhardt, M. Soucheray, M. J. Bennett, M. Cakir, M.. J. McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. M. Kain, L. Miorin, E. Moreno, Z. C. Naing, Y. Zhou, S. Peng, Y. Shi, Z. Zhang, W. Shen, I. T. Kirby, J. E. Melnyk, J. S. Chorba, K. Lou, S. A. Dai, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, J. Lyu, C. J. Mathy, T. Perica, K. B. Pilla, S. J. Ganesan, D. J. Saltzberg, R. Rakesh, X. Liu, S. B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.-P. Huang, Y. F. Liu, S. A. Wankowicz, M. Bohn, M. Safari, F. S. Ugur, C. Koh, N. S. Savar, Q. D. Tran, D. Shengjuler, S. J. Fletcher, M. C. O’Neal, Y. Cai, J. C. Chang, D. J. Broadhurst, S. Klippsten, P. P. Sharp, N. A. Wenzell, D. Kuzuoglu-Ozturk, H.-Y. Wang, R. Trenker, J. M. Young, D. A. Cavero, J. Hiatt, T. L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, R. M. Stroud, A. D. Frankel, O. S. Rosenberg, K. A. Verba, D. A. Agard, M. Ott, M. Emerman, N. Jura, M. Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. Enfert, S. Mukherjee, M. Jacobson, H. S. Malik, D. G. Fujimori, T. Ideker, C. S. Craik, S. N. Floor, J. S. Fraser, J. D. Gross, A. Sali, B. L. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrao, M. Vignuzzi, A. García-Sastre, K. M. Shokat, B. K. Shoichet and N. J. Krogan, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature 583 (2020) 459–468; https://doi.org/10.1038/s41586-020-2286-910.1038/s41586-020-2286-9743103032353859
- 66. Y. Jo, L. Jamieson, I. Edoka, L. Long, S. Silal, J. R. C. Pulliam, H. Moultrie, I. Sanne, G. Meyer-Rath and B. E. Nichols, Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa, Open Forum Inectf. Dis. 8(3) (2021) Article ID ofab040 (8 pages); https://doi.org/10.1093/ofid/ofab04010.1093/ofid/ofab040792862433732750
- 67. S. Nile, A. Nile, J. Qiu, L. Lin, X. Jia and G. Kai, COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine Growth Factor Rev. 53 (2020) 66–70; https://doi.org/10.1016/j.cytogfr.2020.05.00210.1016/j.cytogfr.2020.05.002720466932418715
- 68. M. H. Ahmed and A. Hassan. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review, SN Compr. Clin. Med. 2 (2020) 2637–2646; https://doi.org/10.1007/s42399-020-00610-810.1007/s42399-020-00610-8759912133163859